| Aura Biosciences is a clinical-stage biotechnology company using its targeted oncology platform to develop a potential new standard of care across various cancer indications, with an initial focus on ocular and urologic oncology. Co.'s proprietary platform enables the targeting of a range of solid tumors using Virus-Like Particles that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDC). AU-011, Co.'s VDC candidate, is being developed for the first line treatment of primary choroidal melanoma. In addition, Co. is developing AU-011 for the treatment of non-muscle invasive bladder cancer. The AURA average annual return since 2021 is shown above.
The Average Annual Return on the AURA average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AURA average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AURA average annual return calculation with any dividends reinvested as applicable (on ex-dates).